I-Flash-1800-reagent

I-Flash 1800 Reagents

Key Facts
  • Pack size 2 x50 Tests
  • Very low Percentage CV.
  • High Performance charecteristics based on CLSI standards.
  • Time to result within 12 minutes.
  • 28 days On board reagent stability
  • 28 days Calibration stability
  • Built in Calibrators for all Parameters
  • Unique menu
    • Infectious disease : SARS-CoV-2 IgG,SARS-CoV-2 IgM
    • Reproductive Health : AMH, Inhibin B,Inhibin A, FSH.
    • Diabetes : Adiponectin, GAD A, ZnT8A,Insulin,C Peptide, Cortisol
    • Liver Fibrosis : HA, PIIIPN-P, COL IV, Laminin
    • Anemia : Ferritin, Folate, Vit B12
    • Cardiac Markers : BNP,Myoglobin
    • Routine : Thyroid, Fertility, Tumour Markers*
      (*Coming soon)
autoimmune-Infectious-disease

I-Flash 1800 COVID-19

Key Facts

YHLO has introduced an effective automated CLIA testing for 2019-nCoV IgG/IgM.

CPC is the first company to launch the automated CLIA platform iFlash 1800 in INDIA, facilitating the fastest screening for COVID -19.

YHLO’s new 2019-nCoV IgG/IgM CLIA assays has the following advantages:

  • Fast reporting : 27 min.
  • Ease of sample collection : Serum or EDTA plasma.
  • Automated Assay : CLIA platform- 180 test/hr & 300 tests /hr.
  • Test Pack : 2 x 50 tests with builtin calibrators.
  • On board Stability : 28 days after opening.
  • Calibration stability : 28 days
First CLIA Assays

It is the first company to develop a CLIA platform for 2019-nCoV IgG and IgM antibodies which can satisfy the clinical needs to detect antibodies for new 2019-nCoV and offer differential diagnosis to doctors.

Fast Speed

iFlash 1800 offers comprehensive CLIA solutions up to 180 T/H for detecting 2019-nCoV . Fastest reporting in 27 min.

Stable Raw Materials

With a strong R&D team in protein engineering and immunoassay, YHLO achieves stable supply of the raw materials for these CLIA assays.

Strong Anti-Interference Ability

YHLO has made initial evaluation of these assays, and results showed that these assays have strong anti-interference ability to other respiratory pathogens (e.g. legionella Pneumophila, Mycoplasma Pneumonia, Chlamydia Pneumonia, Q Fever from Rickettsia, Adenovirus, RSV-Respiratory Syncytial Virus, Influenza A, Influenza B, Parainfluenza 1, 2, 3, etc.)

For more information please visit the website of YHLO with the below url:

Performance of SARS-CoV-2 IgM/IgG Kits in Thailand.
Contribution to Wuhan with SARS-CoV-2 IgG/IgM Assays.